Cargando…
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
In the last decade, cancer became the leading cause of death in the population under 65 in the European Union. Diabetes is also considered as a factor increasing risk of cancer incidence and mortality. Type 2 diabetes is frequently associated with being overweight and obese, which also plays a role...
Autor principal: | Dąbrowski, Mariusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915237/ https://www.ncbi.nlm.nih.gov/pubmed/33562380 http://dx.doi.org/10.3390/ijms22041680 |
Ejemplares similares
-
Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
por: Kitamura, Koichi, et al.
Publicado: (2020) -
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
por: Huang, Keming, et al.
Publicado: (2023) -
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
por: Tentolouris, Anastasios, et al.
Publicado: (2019) -
Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i
por: Velasco de Cos, Guillermo, et al.
Publicado: (2021) -
SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)